News | February 01, 2024
Zydus Lifesciences launches Rexigo
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Combines biocompatibility, heat-resistance, transparency and durability
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
Subscribe To Our Newsletter & Stay Updated
